---
title: "LENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume on Analyst Upgrade"
description: "LENZ Therapeutics (NASDAQ:LENZ) experienced a surge in trading volume after Raymond James Financial upgraded its price target from $39.00 to $40.00, maintaining an outperform rating. The stock traded "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251300374.md"
published_at: "2025-08-02T15:29:14.000Z"
---

# LENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume on Analyst Upgrade

> LENZ Therapeutics (NASDAQ:LENZ) experienced a surge in trading volume after Raymond James Financial upgraded its price target from $39.00 to $40.00, maintaining an outperform rating. The stock traded 415,673 shares, a 73% increase from the previous session. Other brokerages, including HC Wainwright and Citigroup, also raised their price targets, with consensus ratings indicating a buy. The stock's market cap is $848.16 million, and it reported a quarterly EPS of ($0.53), beating estimates. LENZ focuses on developing therapies for vision improvement, with products in Phase III trials.

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) saw strong trading volume on Friday after Raymond James Financial raised their price target on the stock from $39.00 to $40.00. Raymond James Financial currently has an outperform rating on the stock. 415,673 shares were traded during trading, an increase of 73% from the previous session's volume of 239,685 shares.The stock last traded at $30.08 and had previously closed at $29.77.

A number of other brokerages also recently commented on LENZ. HC Wainwright reiterated a "buy" rating and issued a $48.00 price objective (up previously from $38.00) on shares of LENZ Therapeutics in a research report on Monday. Citigroup reissued a "buy" rating and issued a $49.00 target price (up from $45.00) on shares of LENZ Therapeutics in a report on Thursday. Finally, Piper Sandler initiated coverage on LENZ Therapeutics in a report on Monday, April 14th. They issued an "overweight" rating and a $51.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $49.60.

Get **LENZ Therapeutics** alerts:

**View Our Latest Research Report on LENZ Therapeutics**

## Institutional Investors Weigh In On LENZ Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new stake in LENZ Therapeutics during the 4th quarter valued at $46,000. Tower Research Capital LLC TRC increased its holdings in LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after purchasing an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in LENZ Therapeutics in the 4th quarter valued at $67,000. Banque Transatlantique SA bought a new position in LENZ Therapeutics in the 1st quarter valued at $119,000. Finally, GAMMA Investing LLC boosted its position in LENZ Therapeutics by 5,254.1% in the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after buying an additional 5,727 shares during the last quarter. 54.32% of the stock is owned by institutional investors and hedge funds.

## LENZ Therapeutics Stock Performance

The stock has a market capitalization of $848.16 million, a P/E ratio of -15.92 and a beta of 0.42. The stock has a 50-day simple moving average of $30.99 and a 200 day simple moving average of $26.90.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.05. The firm had revenue of $5.00 million during the quarter, compared to the consensus estimate of $5.00 million. Equities analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.

## About LENZ Therapeutics

(Get Free Report)

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

## Featured Articles

-   Five stocks we like better than LENZ Therapeutics
-   About the Markup Calculator
-   Rocket Lab Reports Next Week: Here’s What Investors Should Know
-   Compound Interest and Why It Matters When Investing
-   Apple Stock: Big Earnings, Small Move—Time to Buy?
-   Russell 2000 Index, How Investors Use it For Profitable Trading
-   Amazon's Earnings: What Comes Next and How to Play It

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in LENZ Therapeutics Right Now?

Before you consider LENZ Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.

While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [LENZ.US - LENZ Therapeutics](https://longbridge.com/en/quote/LENZ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| LENZ Therapeutics：VIZZ 的早期发布、针对性的直接面向消费者活动以及差异化的老花眼特征支持买入评级 | 威廉·布莱尔分析师拉赫兰·汉伯里·布朗对 LENZ Therapeutics 维持买入评级，原因是其商业进展和 “Make it VIZZable” 宣传活动的启动，该活动旨在教育老花眼患者。该活动的数字策略预计将增强患者获取。汉伯里·布朗 | [Link](https://longbridge.com/en/news/272595337.md) |
| LENZ Therapeutics 签署了 VIZZ 在中东地区的独家分销协议 | Lenz Therapeutics Inc. 与 Lunatus Marketing & Consulting FZCO 签署了一项独家分销协议，旨在在中东地区推广 VIZZ，这是一种用于治疗老花眼的 aceclidine 眼用溶液。Len | [Link](https://longbridge.com/en/news/271516521.md) |
| 每千次展示 60 美元！OpenAI 用高价拉开 “AI 广告” 大幕 | 为应对 AI 巨额开支，OpenAI 正式测试广告，CPM60 美元起步、最低投入 20 万美元，定位高端渠道，直接挑战谷歌万亿美元市场，WPP 等顶级代理已率先合作。但转型风险并存：需平衡用户信任，承诺不用私聊数据；对手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) |
| 领先汽车配件的沉重债务负担加剧了流动性、再融资以及业务扭转的风险 | Advance Auto Parts Inc (AAP) 正面临重大财务风险，主要由于其沉重的债务负担，这可能限制流动性和融资渠道。这种情况可能迫使更多现金流用于偿债，而非投资，从而增加对经济衰退和潜在契约违约的脆弱性。在严峻的信贷环境中， | [Link](https://longbridge.com/en/news/275997122.md) |
| 伊本·阿尔·海赛姆医院全年收入为 301,281 第纳尔 | 伊本·海瑟姆医院公司 PSC (IBNH.AM)：伊本·海瑟姆医院财年税后净收入为 301,281 第纳尔；伊本·海瑟姆医院财年收入为 1210 万第纳尔 | [Link](https://longbridge.com/en/news/275996849.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
